Last quarter (Q4 2023), Kazia Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Kazia Therapeutics's net income was $―. See Kazia Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ ―	$ ―	$ ―	$ 15.18M	$ 0.00	$ 0.00
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ 15.18M	$ ―	$ ―
Operating Expense	$ ―	$ 24.15M	$ 24.76M	$ 21.56M	$ 12.19M	$ 8.82M
Operating Income	$ ―	$ -24.15M	$ -24.76M	$ -21.56M	$ -12.19M	$ -8.82M
Net Non Operating Interest Income Expense	$ ―	$ -22.00K	$ 2.00K	$ 15.22M	$ 66.00K	$ 100.00K
Other Income Expense	$ ―	$ 3.39M	$ 24.89M	$ 10.99M	$ -637.00K	$ -1.85M
Pretax Income	$ ―	$ -20.74M	$ -25.02M	$ -8.91M	$ -12.77M	$ -10.57M
Tax Provision	$ ―	$ -271.00K	$ -368.00K	$ -484.00K	$ -298.00K	$ -298.00K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -20.46M	$ -73.90M	$ -25.26M	$ -12.47M	$ -10.27M
Basic EPS	$ ―	$ -0.11	$ -0.19	$ -0.07	$ ―	$ ―
Diluted EPS	$ ―	$ -0.11	$ -0.19	$ -0.07	$ ―	$ ―
Basic Average Shares	$ ―	$ 184.28M	$ 388.94M	$ 360.91M	$ ―	$ ―
Diluted Average Shares	$ ―	$ 184.28M	$ 388.94M	$ 360.91M	$ ―	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 24.15M	$ 24.76M	$ 21.56M	$ 12.19M	$ 8.82M
Net Income From Continuing And Discontinued Operation	$ ―	$ -20.46M	$ -73.90M	$ -25.26M	$ -12.47M	$ -10.27M
Normalized Income	$ ―	$ ―	$ ―	$ ―	$ -11.84M	$ -8.45M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ ―	$ -25.02M	$ -8.91M	$ -12.19M	$ -8.82M
EBITDA	$ ―	$ ―	$ -23.06M	$ -7.64M	$ -11.11M	$ -7.74M

Currency in USD

Kazia Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing